Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRIS 
Curis Inc (CRIS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: CRIS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.33
1 Year Target Price $16.33
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.1% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.00M USD | Price to earnings Ratio - | 1Y Target Price 16.33 |
Price to earnings Ratio - | 1Y Target Price 16.33 | ||
Volume (30-day avg) 5 | Beta 3.65 | 52 Weeks Range 1.02 - 8.29 | Updated Date 08/14/2025 |
52 Weeks Range 1.02 - 8.29 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -1.515 | Actual -0.68 |
Profitability
Profit Margin - | Operating Margin (TTM) -300.15% |
Management Effectiveness
Return on Assets (TTM) -59.59% | Return on Equity (TTM) -2951.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13669027 | Price to Sales(TTM) 1.84 |
Enterprise Value 13669027 | Price to Sales(TTM) 1.84 | ||
Enterprise Value to Revenue 1.2 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 12498900 | Shares Floating 10418419 |
Shares Outstanding 12498900 | Shares Floating 10418419 | ||
Percent Insiders 7.23 | Percent Institutions 37.09 |
Upturn AI SWOT
Curis Inc
Company Overview
History and Background
Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Founded in 2000, it has undergone shifts in its focus, initially exploring diverse research areas before concentrating on cancer therapeutics. Key milestones include the development of Erivedge (vismodegib) through a collaboration with Genentech, and subsequent focus on other targeted therapies.
Core Business Areas
- Drug Development: Curis is primarily focused on the discovery, development, and commercialization of novel therapeutics targeting cancer. This includes preclinical and clinical research, manufacturing, and regulatory activities.
Leadership and Structure
The leadership team includes key executives responsible for research and development, clinical operations, finance, and business development. The organizational structure involves departments dedicated to drug discovery, clinical trials, and corporate functions.
Top Products and Market Share
Key Offerings
- CI-8993: A first-in-class oral IRAK4 inhibitor targeting cancers dependent on IRAK4 signaling. Currently in clinical development. Market share is not yet applicable as it is not commercially available. Competitors include companies developing similar IRAK4 inhibitors or therapies targeting related pathways.
- Fimepinostat: An oral dual HDAC and PI3K inhibitor. Currently in clinical development. Market share is not yet applicable as it is not commercially available. Competitors include companies developing HDAC or PI3K inhibitors.
Market Dynamics
Industry Overview
The biotechnology industry, particularly in oncology, is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The industry is driven by the unmet needs of cancer patients and advancements in drug discovery technologies.
Positioning
Curis is a clinical-stage biotechnology company focusing on targeted cancer therapies. It seeks to differentiate itself through innovative drug candidates with unique mechanisms of action. Its competitive advantage lies in its proprietary drug discovery platform and clinical development expertise.
Total Addressable Market (TAM)
The global oncology market is estimated to be in the hundreds of billions of USD. Curis is targeting specific subsets of cancers where its therapies could have a significant impact. Their positioning within the TAM is dependent on successful clinical trials and commercialization, which would allow them to capture a meaningful portion of the targeted market segments.
Upturn SWOT Analysis
Strengths
- Innovative drug candidates in clinical development
- Targeted therapy approach
- Experienced management team
- Proprietary drug discovery platform
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- High risk of drug development failure
- Small market capitalization
Opportunities
- Potential for breakthrough therapies
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through drug discovery
- Market approval and commercialization of drug candidates
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent expirations
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- AbbVie (ABBV)
- Bristol Myers Squibb (BMY)
- Merck & Co (MRK)
- Johnson & Johnson (JNJ)
Competitive Landscape
Curis faces stiff competition from larger pharmaceutical companies with significantly more resources. Its success depends on differentiating itself through innovative therapies, targeted treatments, and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth must be determined from the company's financial statements and filings.
Future Projections: Future growth is dependent on the success of clinical trials and commercialization. Analyst estimates fluctuate.
Recent Initiatives: Recent initiatives include advancements in clinical trials, new drug discovery, and strategic partnerships.
Summary
Curis is a clinical-stage biotech focusing on cancer therapies and faces financial limitations typical of its size and stage, needing clinical trial success to achieve sustainability. The companyu2019s strength lies in its novel drug candidates and discovery platform, balanced against the risks inherent in drug development. Partnerships and successful trials are crucial for its growth, while competition and regulatory changes remain significant challenges. Further monitoring is required, especially in terms of financial metrics and clinical trial outcomes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Curis Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-08-01 | President, CEO, Secretary, Treasurer & Director Mr. James E. Dentzer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.curis.com |
Full time employees 34 | Website https://www.curis.com | ||
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.